Celebrating the great minds that bring us innovation in small molecules, biopharmaceuticals, and advanced medicine.
A repurposed drug could help improve immunotherapy response rates.
We must collaborate to address stability challenges in viral vector manufacturing.
Intel shows a rise in cell and gene therapy development in the US, with China not far behind.
Tackling solid tumors with macrophages, a stem cell cure for HIV, and travel bans… What’s new in advanced medicine?
In what may have been one of the last advanced therapy meetings to go ahead for some time, delegates met in London in late February for CAR-TCR.
How can manufacturing be improved for viral vectors?
Sitting Down With… Mike McMullen, President and CEO, Agilent Technologies, Santa Clara, California, USA.
Claudia Zylberberg explains the importance of ancillary material quality for advancing cell and gene therapies.
The world’s largest cell and gene CDMO, an exciting new TCR, and the global CAR T picture… We examine what’s going on in advanced medicine.
Gene therapies (including CAR T) could add $45 billion to US healthcare costs over the next five years, a CVS health report finds.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.